Cargando…

Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor

The increasing use of patient-administered oral anticancer drugs is paralleled by new challenges in maintaining treatment adherence. These challenges are particularly significant with adjuvant therapies for prevention of disease recurrence, where the benefits of ongoing treatment are not readily app...

Descripción completa

Detalles Bibliográficos
Autores principales: Tetzlaff, Eric D., Davey, Monica P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093429/
https://www.ncbi.nlm.nih.gov/pubmed/25032004
_version_ 1782325727146803200
author Tetzlaff, Eric D.
Davey, Monica P.
author_facet Tetzlaff, Eric D.
Davey, Monica P.
author_sort Tetzlaff, Eric D.
collection PubMed
description The increasing use of patient-administered oral anticancer drugs is paralleled by new challenges in maintaining treatment adherence. These challenges are particularly significant with adjuvant therapies for prevention of disease recurrence, where the benefits of ongoing treatment are not readily apparent to patients. Nurse practitioners and physician assistants (collectively referred to as advanced practitioners) play integral roles in providing education on disease and treatment to patients that can increase adherence to oral therapies and ideally improve outcomes. For patients with gastrointestinal stromal tumor (GIST), the oral targeted therapy imatinib has become the mainstay of treatment for advanced and recurrent disease and as adjuvant therapy following surgical resection. Recent data indicate significantly improved overall survival with 3 years vs. 1 year of adjuvant imatinib therapy. Continuous dosing with imatinib is needed for optimal efficacy and to limit additional health-care costs associated with management of disease progression in GIST. However, longer duration of therapy increases the risk of nonadherence. Imatinib adherence rates, as well as factors contributing to nonadherence to adjuvant therapy in routine clinical practice, are discussed in this review. Also explored are practical approaches for improving adherence to adjuvant imatinib therapy through greater patient education, in light of the increased duration of therapy in select patients.
format Online
Article
Text
id pubmed-4093429
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Harborside Press
record_format MEDLINE/PubMed
spelling pubmed-40934292014-07-16 Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor Tetzlaff, Eric D. Davey, Monica P. J Adv Pract Oncol Review Article The increasing use of patient-administered oral anticancer drugs is paralleled by new challenges in maintaining treatment adherence. These challenges are particularly significant with adjuvant therapies for prevention of disease recurrence, where the benefits of ongoing treatment are not readily apparent to patients. Nurse practitioners and physician assistants (collectively referred to as advanced practitioners) play integral roles in providing education on disease and treatment to patients that can increase adherence to oral therapies and ideally improve outcomes. For patients with gastrointestinal stromal tumor (GIST), the oral targeted therapy imatinib has become the mainstay of treatment for advanced and recurrent disease and as adjuvant therapy following surgical resection. Recent data indicate significantly improved overall survival with 3 years vs. 1 year of adjuvant imatinib therapy. Continuous dosing with imatinib is needed for optimal efficacy and to limit additional health-care costs associated with management of disease progression in GIST. However, longer duration of therapy increases the risk of nonadherence. Imatinib adherence rates, as well as factors contributing to nonadherence to adjuvant therapy in routine clinical practice, are discussed in this review. Also explored are practical approaches for improving adherence to adjuvant imatinib therapy through greater patient education, in light of the increased duration of therapy in select patients. Harborside Press 2013 2013-07-01 /pmc/articles/PMC4093429/ /pubmed/25032004 Text en Copyright © 2013, Harborside Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is for non-commercial purposes.
spellingShingle Review Article
Tetzlaff, Eric D.
Davey, Monica P.
Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
title Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
title_full Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
title_fullStr Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
title_full_unstemmed Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
title_short Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
title_sort optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093429/
https://www.ncbi.nlm.nih.gov/pubmed/25032004
work_keys_str_mv AT tetzlaffericd optimizingadherencetoadjuvantimatinibingastrointestinalstromaltumor
AT daveymonicap optimizingadherencetoadjuvantimatinibingastrointestinalstromaltumor